Welela Tereffe named chief medical executive at MD Anderson

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Welela Tereffe was named chief medical executive of MD Anderson Cancer Center.

Tereffe began the position and joined the institution’s Executive Leadership Team Jan. 1. Previously, Tereffe served as the institution’s chief medical officer, a position she held for two years.

In this role, Tereffe will engage physicians and advanced practice providers in the delivery of research-driven clinical care that includes the Texas Medical Center campus, community and academic settings in Texas and MD Anderson Cancer Network. She will work closely with leadership to recruit faculty, promote research excellence and enhance the wellness and development of providers.

“Welela is a servant leader with strong emotional intelligence and drive. She has intimate knowledge of medical practice, extensive understanding of academic health care, and is known for partnering and engaging others,” Peter WT Pisters, president of MD Anderson, said in a statement. “Her commitment to MD Anderson, to our providers and—most importantly—to our patients is undeniable. She is passionate about improving equity in access to safe, quality care, and to reducing disparities in cancer care and outcomes. We welcome her to our Executive Leadership Team.”

Since joining MD Anderson in 2005, Tereffe has earned a Master of Public Health in 2009, and currently she is working toward a Master of Health Care Management at the Harvard School of Public Health.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login